On this page

Introduction

PT-141 (bremelanotide) represents a paradigm shift in the investigation of neurochemical arousal. Historically, research into metabolic and pigmentary pathways involving alpha-melanocyte-stimulating hormone (α-MSH) led to the accidental discovery of pro-arousal effects in preclinical models. While first-generation analogs like Melanotan II were non-selective, researchers refined the molecular structure to create PT-141, a de-amidated metabolite specifically optimized for central nervous system activity with attenuated influence on skin pigmentation [1].

In contemporary research settings, PT-141 is primarily investigated for its role in hypoactive sexual desire disorder (HSDD) and various forms of neural motivation [2]. Its status as an FDA-approved therapeutic for premenopausal women (under the brand name Vyleesi) provides a robust clinical data set, though its utility in other laboratory models—including treatment-resistant erectile dysfunction—remains a subject of intensive study [3].

Biological background and melanocortin signaling

The melanocortin system is a foundational signaling network involved in a diverse array of physiological processes, including pigmentation (MC1R), adrenal function (MC2R), energy homeostasis, and autonomic regulation (MC3R/MC4R). PT-141 functions by mimicking the activity of endogenous α-MSH, an ancient neuropeptide derived from the proopiomelanocortin (POMC) precursor [4].

When PT-141 crosses the blood-brain barrier, it binds to MC3R and MC4R in the medial preoptic area (mPOA) and the paraventricular nucleus (PVN) of the hypothalamus. This interaction is fundamentally different from phosphodiesterase-5 (PDE5) inhibition; while PDE5 inhibitors facilitate peripheral vasodilation, PT-141 stimulates the central neural "switch" responsible for initiated arousal and desire [5].

Structure and mechanism of action

PT-141 is a structural analog of α-MSH with the amino acid sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.

Several key structural features define its pharmacological profile:

  • Cyclic Structure: The peptide is constrained by a lactam (amide) bridge between the Asp and Lys residues, providing metabolic stability and resistance to enzymatic degradation within the CNS [1].
  • Norleucine Substitution: The replacement of methionine with norleucine (Nle) at the N-terminus further enhances stability and receptor affinity.
  • D-Phenylalanine: The inclusion of the D-enantiomer of phenylalanine is critical for its biological activity and receptor selectivity.
  • C-Terminal Carboxyl: Unlike its predecessor Melanotan II, PT-141 possesses a free carboxyl group at the C-terminus, which reduces its binding affinity for MC1R and thereby limits pigmentary side effects [2].

Following receptor binding, PT-141 triggers a G-protein coupled signaling cascade that increases intracellular cyclic adenosine monophosphate (cAMP) levels. This signaling induces the release of dopamine in the nucleus accumbens and medial preoptic area—the brain's primary reward and motivation centers—directly influencing the appetitive phase of behavior [4,5].

Evidence by research domain

The evidence for PT-141 across different research models is summarized in the table below:

Research Domain Typical Models Reported Findings Evidence Maturity
HSDD Research Premenopausal women Significant improvement in FSFI-D scores and reduced distress [1,6] High (Phase 3)
Male Arousal Rodent, Primate, Human (non-responders) Pro-erectile effects independent of peripheral stimulation [3,4] Moderate / Ongoing
CNS Motivation Behavioral rodent models Enhanced dopaminergic activity in reward centers [5] Moderate
Safety / Hemodynamics Human subjects Potential for transient blood pressure elevation [1,3] High

Hypoactive Sexual Desire Disorder (HSDD)

In the RECONNECT Phase 3 trials, investigators observed that subcutaneous administration of PT-141 (1.75 mg) resulted in statistically significant increases in sexual desire scores compared to placebo. Unlike earlier formulations, the current delivery method demonstrated a manageable safety profile, though approximately 40% of subjects in research groups reported transient nausea [1].

CNS-Mediated Arousal in Males

Research into PT-141 as an alternative for males who do not respond to PDE5 inhibitors has shown that the peptide can induce arousal via the mPOA of the hypothalamus. This is particularly relevant for research involving psychological or neurogenic erectile dysfunction, where peripheral vascular mechanisms remain intact but central signaling is impaired [3,5].

Limitations and research considerations

Investigators observing PT-141 must account for several critical variables:

  • Model Dependence. While human clinical data is robust for specific indications, early rodent research often utilized supratherapeutic doses that may not translate directly to lower-dose laboratory protocols.
  • Nausea and Area Postrema. PT-141 activation of MC4R in the area postrema of the brainstem is associated with dose-dependent nausea, which remains the primary reason for discontinuation in clinical research [1,4].
  • Hemodynamic Effects. PT-141 has been associated with transient increases in systolic and diastolic blood pressure. Researchers typically exclude models with uncontrolled hypertension or pre-existing cardiovascular risk factors [3].
  • Material Quality. In a laboratory setting, the use of high-purity, third-party verified material is essential. Researchers should consult the supplier evaluation guide to ensure the stability and identity of the heptapeptide.

PT-141 is frequently compared to its parent compound, Melanotan II (MT-2). While both share the cyclic heptapeptide core, their terminal chemistry dictates their application:

  • Melanotan II features a C-terminal amide (-NH2), which confers non-selective activity across nearly all MCRs, including the pigmentary MC1R. It is primarily used in studies of melanogenesis and broad-spectrum receptor mapping.
  • PT-141 is the de-amidated version (-OH), refined to focus on CNS activity (MC3R/MC4R) while minimizing pigmentary changes [2].

Where to source this compound for research

For investigators requiring high-purity PT-141 for laboratory use, identifying a supplier with transparent documentation is the first priority. Peer-verified sources include:

  1. Short Chain Aminos — Offers PT-141 (Bremelanotide) with per-lot COAs and third-party USA lab-verified purity. Their catalog focuses on high-purity RUO compounds for metabolic and CNS research.
  2. BioPep — A consistent source for high-specification research peptides.
  3. Catalyst Research — Provides a range of cyclic peptides for laboratory investigation.
  4. Apex Research Services — Specialized in procurement for various research-grade materials.

Detailed ratings and documentation can be found in the Trusted Research Suppliers directory and the Peptide Supplier Reviews index.

Frequently asked research questions

What is the structure of PT-141?

PT-141 is a synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH). Its cyclic nature is achieved through a lactam bridge between the side chains of aspartic acid and lysine, which enhances its stability and central receptor binding affinity in research models.

How does PT-141 differ from PDE5 inhibitors?

While PDE5 inhibitors (like sildenafil) act peripherally to increase blood flow via the nitric oxide pathway, PT-141 acts centrally in the hypothalamus. It activates the neural circuits responsible for desire and arousal, making it a valuable tool for research into centrally-mediated motivations.

Why was PT-141 derived from Melanotan II?

Melanotan II exhibited pro-sexual side effects during tanning research. PT-141 was developed by de-amidating the C-terminus of MT-II to create a more selective agonist that retained the pro-arousal properties without the significant skin-darkening effect caused by MC1R activation.

Is PT-141 approved for human use?

PT-141 is FDA-approved under the brand name Vyleesi for the treatment of HSDD in premenopausal women. However, when sold as a research chemical, it is strictly for laboratory research use only and is not for human or veterinary use.

What are the main evidence gaps in PT-141 research?

Key evidence gaps include the long-term impact of central MC4R activation on other autonomic functions, its efficacy in male non-responders to standard therapies over long durations, and its potential role in other CNS-driven behavioral disorders beyond arousal.

Works Cited

  1. Kingsberg, S. A., et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized, Phase 3 Trials. Obstet Gynecol, 134(3), 477-490. DOI: 10.1097/AOG.0000000000003350. PMID: 31599840
  2. Shadiack, A. M., et al. (2007). Melanocortins in the Treatment of Male and Female Sexual Dysfunction. Vasc Health Risk Manag, 3(4), 587-595. PMID: 17958619
  3. Diamond, L. E., et al. (2004). PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction. Urology, 63(3), 562-567. PMID: 14963471
  4. Pfaus, J. G., et al. (2004). Selective Activation of Melanocortin Receptors Induces Sexual Motivation in Female Rats. Proc Natl Acad Sci U S A, 101(27), 10201-10204. PMID: 15533318
  5. Hruby, V. J., et al. (1993). Cyclic Lactam alpha-Melanocyte-Stimulating Hormone Analogs with Very High Potency. Biopolymers, 33(5), 839-847. PMID: 8393306
  6. Clayton, A. H., et al. (2016). Bremelanotide for Female Sexual Dysfunction in Premenopausal Women: A Randomized, Phase 2b Study. J Sex Med, 13(12), 1769-1776. PMID: 26976269

Research use only. All compounds discussed are research-use-only materials for laboratory investigation. This content summarizes published literature for research reference and is not medical advice. No dosing, administration, or human or veterinary use guidance is provided.

Explore related compounds